Anti-cancer activities of pH- or heat-modified pectin by Leclere, L. et al.
RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE
Author(s) - Auteur(s) :
Publication date - Date de publication :
Permanent link - Permalien :
Rights / License - Licence de droit d’auteur :
Bibliothèque Universitaire Moretus Plantin
Institutional Repository - Research Portal
Dépôt Institutionnel - Portail de la Recherche
researchportal.unamur.be
Anti-cancer activities of pH- or heat-modified pectin
Leclere, L.; Cutsem, P.V.; Michiels, C.
Published in:
Frontiers in Pharmacology
DOI:
10.3389/fphar.2013.00128
Publication date:
2013
Document Version
Publisher's PDF, also known as Version of record
Link to publication
Citation for pulished version (HARVARD):
Leclere, L, Cutsem, PV & Michiels, C 2013, 'Anti-cancer activities of pH- or heat-modified pectin' Frontiers in
Pharmacology, vol. 4, pp. 128. https://doi.org/10.3389/fphar.2013.00128
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 21. May. 2019
“fphar-04-00128” — 2013/10/4 — 17:31 — page 1 — #1
REVIEW ARTICLE
published: 08 October 2013
doi: 10.3389/fphar.2013.00128
Anti-cancer activities of pH- or heat-modiﬁed pectin
Lionel Leclere 1, PierreVan Cutsem2 and Carine Michiels 1*
1 Unité de Recherche en Biologie Cellulaire, Namur Research Institute for Life Sciences, University of Namur, Namur, Belgium
2 Unité de Recherche en Biologie Cellulaire Végétale, University of Namur, Namur, Belgium
Edited by:
Pierre Sonveaux, University of
Louvain Medical School, Belgium
Reviewed by:
Marc Poirot, Institut National de la
Santé et de la Recherche Médicale,
France
Hervé Emonard, Centre National de la
Recherche Scientiﬁque, France
*Correspondence:
Carine Michiels, Unité de Recherche
en Biologie Cellulaire, Namur
Research Institute for Life Sciences,
University of Namur, 61 rue de
Bruxelles, 5000 Namur, Belgium
e-mail: carine.michiels@unamur.be
Despite enormous efforts that have been made in the search for novel drugs and
treatments, cancer continues to be a major public health problem. Moreover, the
emergence of resistance to cancer chemotherapy often prevents complete remission.
Researchers have thus turned to natural products mainly from plant origin to circumvent
resistance. Pectin and pH- or heat-modiﬁed pectin have demonstrated chemopreventive
and antitumoral activities against some aggressive and recurrent cancers. The focus of
this review is to describe how pectin and modiﬁed pectin display these activities and
what are the possible underlying mechanisms. The failure of conventional chemotherapy
to reduce mortality as well as serious side effects make natural products, such as pectin-
derived products, ideal candidates for exerting synergism in combination with conventional
anticancer drugs.
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Despite enormous progress in oncology therapy during the last
decade, especially regarding the development of “smart drugs,”
cancer still remains one of the leading causes of death. Hence,
the development of new therapeutic strategies remains a high
priority. Natural compounds represent an important source of
new “leads” with potent chemotherapeutic or chemopreventive
activity. Structure-activity relationship studies have led to the
development of natural molecules or of semi-synthetic analogs
with higher activity or lower toxicity. Two of the best examples
currently used in cancer therapy are paclitaxel and etoposide. In
this review, we will describe what is known about one particular
class of complex plant polysaccharides, pectin, and its potential
anti-cancer activities.
DESCRIPTION OF PECTIN
In 1825, a French chemist and pharmacist, Henri Braconnot, who
was an expert in the extraction of active components from plants,
was the ﬁrst to discover a heteropolysaccharide with gelling prop-
erties which he named “pectic acid” (in ancient Greek πηκτικóς
meaning coagulant).
Pectin is a family of complex polysaccharides, which are found
in high amounts in plant primary wall. The main role of the plant
wall components is to give mechanical strength to plants, to main-
tain an extracellular water phase by imbibition and to provide a
barrier from external environment.
The exact chemical structure of pectin is still under debate.
Pectins are a family of covalently linked galacturonic acid-rich
polymers. Until now, three main pectic polysaccharides have been
isolated from plant wall whose structure has been identiﬁed. They
are homogalacturonan (HG), rhamnogalacturonan-I (RG-I) and
substituted galacturonans (GS).
Homogalacturonan which constitutes about 65% of pectin
molecule is a linear chain of D-galactopyranosyluronic acid
(GalpA) bound in α-1,4. The carboxyl group of some residues
can be methyl-esteriﬁed. According to the plant species, HGs may
also be partly O-acetylated on C-3 or C-2 (Figure 1).
Rhamnogalacturonan-Imakes about 20–35%of pectin. RG-I is
a family of pectic polysaccharides whose main chain is a repetition
of disaccharides composed of galacturonic acid and rhamno-
syl bound [→4)-α-D-GalpA-(1→2)-α-L-Rhap-(1→]. The Galp
residues forming the main chain can be O-acetylated in C-3 or
C-2 but are usually not linked with monomers or lateral chains.
According to the plant species, about 20–80% of the rhamno-
syl residues are substituted with neutral or acidic oligosaccharide
chains on the carbonC4 of rhamnosyl residues. Themost frequent
lateral chains contain α-L-arabinofuranosyl (Araf) and/or galac-
topyranosyl (Galp). These lateral chains (arabinans, galactans or
arabinogalactans) may be linear or branched (Figure 1).
Substituted galacturonans make a group of various polysaccha-
rides whose linear chain is composed of D-GalpA residues linked
in α-1,4 (as in HG) and on which are grafted other residues.
Among these GS, is rhamnogalacturonan-II (RG-II). RG-II has
nothing to do with RG-I, its main chain is not composed of
GalA-Rhap disaccharide but of a HG chain. Four types of chains
with structurally different oligosaccharides are linked to the main
chain of RG-II, they are composed of 12 types of glycosyl residues
bound together by at least 22 types of glycosidic bounds. One
nonasaccharide (lateral chain B) and one octasaccharide (lateral
chain A) are attached in C-2 of some GalA residues from the
main chain and two different disaccharides are linked in C-3 of
the main chain. The localization of these lateral chains one in
relation to the other is not yet determined (Figure 1). RG-II is
often found in dimers thanks to a borate ion located on chain
A. This dimerisation seems essential for the integrity of the plant
cell wall. Despite its complexity, the RG-11 structure is well con-
served in vascularized plants. Very few mutants with modiﬁed
RG-II have been identiﬁed until now, which indicates the impor-
tance to conserve its structure. Other GS have been described
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FIGURE 1 | Schematic representation of pectin structure. AG, arabinogalactan; HG, homogalacturonan; RG, rhamnogalacturonan; XG, xylogalacturonan.
in a short number of plants. Xylogalacturonan contains β-D-
xylosyl (Xylp) linked in C3 of the main chain and is present in
reproductory tissues of plants like apple, carrot and cotton. Apio-
galacturonan contains monomers or dimers of β-D-apioduranosyl
(Apif) attached in C-2 and C-3 of the main chain. Apiogalac-
turonan is found in some monocotyledons (Ridley et al., 2001;
Mohnen, 2008; Caffall and Mohnen, 2009; Harholt et al., 2010;
Figure 1).
The most accepted model for pectin structure is a main back-
bone of HG in which are intercalated regions of RG-I, RG-II and
GS (Caffall and Mohnen, 2009). There are linkages between pectin
polysaccharides as well as to other wall molecules, combined to
make a network that makes the primary cell wall.
FUNCTION OF PECTIN IN PLANT CELL WALL
As mentioned here above, the role of the components of the plant
cell wall is ﬁrst to give mechanical solidity and to form a barrier
from the external environment. HGs and RGII are known to be
responsible for the wall rigidiﬁcation. HGs have the property to
form structures which are named “egg boxes.” Two HG chains are
bound one to the other through interactions including bivalent
Ca2+ ions intercalated in between them (Liners et al., 1989). This
process is important for the gelling of pectin.
The mechanical role of RG-I has been less studied but it seems
that RG-I may play a role in cell wall plasticity, for example by
preventing HG chains to interact with Ca2+ ions. Transgenic
plants with decreased amounts of arabinans and galactans display
a stiffening of their cell wall.
Pectin organization and composition in plant primary cell wall
depend on the growth state of the plant, on the tissues and on the
plant species. Its synthesis is a complex process involving numer-
ous enzymes that are just becoming to be identiﬁed (Atmodjo
et al., 2013).
BIOLOGICAL ACTIVITIES OF OLIGOGALACTURONIDES IN PLANTS
There are three different ways for a pathogen to enter into a plant:
to go through a natural opening, such as stomata; to seep into
a wound or to digest the cell wall. Pectin is then the ﬁrst sub-
strate. Pathogens are able to secrete endopolygalacturonases and
endopectate lyases which degrade HGs present in the cell wall
and then release oligogalacturonides (OGAs). OGAs are biologi-
cally active carbonhydrates which act as signal molecules initiating
defense responses from the plant. The ﬁrst defense response
observed in response to OGA production is the production of
reactive oxygen species such as H2O2 and O
−
2 . OGAs also initi-
ate signaling pathways that activate defense systems in plants, like
the production of protease inhibitors able to block the activity of
proteases secreted by insects to digest plant cell wall. Finally OGAs
are also responsible forwall reinforcement in response to pathogen
infection. In addition to their roles in plant defense systems,OGAs
Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs October 2013 | Volume 4 | Article 128 | 2
“fphar-04-00128” — 2013/10/4 — 17:31 — page 3 — #3
Leclere et al. Anti-cancer properties of pectin
also inﬂuence plant growth and development and they play a role
in fruit ripening.
PECTIN ACTIVITIES IN HUMAN BEINGS
Since humans are able to extract pectin, they try to use its huge
potential to their beneﬁts. In addition to be used as a gelling agent
in food industry, pectin displays properties useful in medicine
(Lattimer and Haub, 2010). In humans, pectin, as a dietary ﬁber,
is not enzymatically digested in the small intestine but is degraded
by microbia in colon. It keeps its gelling action in the digestive
track, so that it slows down digestion. This is very beneﬁcial in
patients with Dumping syndrome who have a too rapid digestion
within their stomach (Lawaetz et al., 1983). Pectin is also capable
of diminishing blood cholesterol level and of stimulating lipid
excretion. However, the exactmechanisms underlying these effects
are not known yet (Brown et al., 1999). Pectin is also investigated
for its ability to increase 137Cs clearance (Nesterenko et al., 2004).
137Cs is a radio-isotope produced during uranium ﬁssion that is
found in Tchernobyl area. PectaSol®, a modiﬁed form of pectin,
when eaten during several days, allows a better clearance via the
urinary track of toxic elements like arsenic or cadmium, which
seem to be chelated by modiﬁed pectin and then eliminated in the
urine (Eliaz et al., 2006). Finally, several studies have shown that
orally taken pectin decreases the risk of intestinal infection and of
diarrhea in children by favoring the growth of “good” bacteria in
the colon (e.g., Bifﬁdobacteria and Lactobacillus) to the detriment
of pathogenic bacteria (Olano-Martin et al., 2002).
PECTIN AND CANCER, STATE OF THE ART
Pectin is known for its anti-tumor activities already since several
decades. Because of its highly complex structure, it is not surpris-
ing that it displays so many different biological activities (Maxwell
et al., 2012). In the literature, it is not easy tomake the link between
structure and pectin bioactivity, notably because the origin of the
pectin used in the different studies and the possible chemicalmod-
iﬁcations that create molecular fragments it has undergone are not
always well described. It has to be noted that differences in size of
the fragments generated, in their degree of esteriﬁcation (DE), in
the nature of the sugar monomers present in the polysaccharide(s)
and the extraction procedure are likely to have signiﬁcant inﬂu-
ence on the properties on these different types of pectin. However,
six main issues will be highlighted hereunder.
EFFECT OF PECTIN AS A DIETARY FIBER
As a dietary ﬁber, pectin plays a role in preventing colon cancer.
In 1979, Watanabe et al. (1979) have shown that rats treated with
azoxymethane or methylnitrosourea develop less colon tumors
if their diet was enriched in pectin. Heitman et al. (1992) sim-
ilarly demonstrated less numerous colon tumors in rats treated
with 1,2-dimethylhydrazine if they were given pectin. Ohkami
et al. (1995) evidenced that citrus and apple pectin in the diet of
rats exposed to azoxymethane decreased carcinogenesis. The two
types of pectin decreased the number of tumors and apple pectin
decreased the activity of β-glucuronidase, an enzyme from fecal
bacteria whose activity is correlated to colon cancer development
(Ohkami et al., 1995). Different types of carbohydrates have been
studied for their antimutagenic activity. For example, Hensel and
Meier (1999) showed that xyloglucans and rhamnogalacturonans
decreased themutagenic effect of 1-nitropyrene. This protection is
dose-dependent and could come from a direct interaction between
cells and polymers that would protect the cells from mutagenic
effects of 1-nitropyrene.
Colon carcinogenesis is a multi-step process that results from
disruption of the balance between proliferation of colonocytes at
the base of the crypt and loss of colonocytes at the luminal sur-
face due to apoptosis. Most colon cancer cells become resistant
to apoptosis, hence promoting tumor growth. Chemoprotection
may arise if luminal colonocyte sensitivity to apoptosis is restored.
Schwartz’s team ﬁrst showed that in rats, a pectin rich diet, com-
pared to a standard diet, favored the expression of caspase-1
in luminal colonocytes from colon crypts and increased cleaved
PARP level in basal and luminal colonocytes. The expression of
the anti-apoptotic protein Bcl2 is on the other hand higher in rats
with standard diet (Avivi-Green et al., 2000c). They then demon-
strated that the activation of apoptosis due to the pectin rich diet
had protective effects and diminished the number and the size
of tumors in rats treated with 1,2-dimethylhydrazine. Colono-
cytes of rats nourished with pectin presented a high activity of
caspase-1 and expressed pro-caspase-3 at a higher level, with a
higher level of cleaved PARP. Pectin per se may induce apoptosis
since the viability of cells exposed in culture to different pectin-
derived oligosaccharides is decreased. Olano-Martin et al. (2003)
evidenced that when colon adenocarcinomaHT29 cells were incu-
bated in the presence of pectin oligosaccharides during 3 days, an
increase in apoptosis, in DNA fragmentation and in caspase-3
activity was observed. This is also true for cells from other types
of cancer: Attari et al. (2009) demonstrated that concentrations
of 100 μg/ml to 1 mg/ml of pectic acids induced apoptosis in rat
GH3/B6 pituitary tumor cells in a concentration dependent way
while concentrations of 2.5 and 5.0 mg/ml induced necrosis. DNA
fragmentation which was directly proportional to the number of
apoptotic cells was observed (Attari et al., 2009). In combina-
tion with n-3 polyunsaturated fatty acid-rich ﬁsh oil, pectin also
demonstrated chemoprevention in a colon cancer model of rats
injected with azoxymethane. This was associated with a decrease
in Bcl-2 expression due to promoter methylation (Cho et al., 2012)
as well as to changes in the expression proﬁle of mRNA implicated
in and of miRNA targeting canonical oncogenic signaling pathway
(Davidson et al., 2009; Cho et al., 2011; Shah et al., 2011).
On the other hand, colonocyte apoptosis activation in ani-
mals fed with pectin is also largely due to butyrate, a molecule
coming from pectin fermentation by colon bacteria ﬂora (Avivi-
Green et al., 2000a,b). Indeed, intracolonic instillation of butyrate
recapitulates the effect of orally administered pectin (Avivi-Green
et al., 2000b). Butyrate is also able to induce apoptosis in colono-
cytes in vitro in a p53-independent manner (Kolar et al., 2007)
and by inducing mitochondrial Ca2+ overload (Kolar et al., 2011).
In parallel, both in vitro in rat intestinal epithelial cells exposed
to butyrate and in mice fed with a diet supplemented with 20%
pectin, TGF-ß signaling has been demonstrated to be enhanced,
leading to colonocyte growth inhibition and apoptosis. Apoptosis
seems to be induced via an increased expression of Id2 (inhibitor
of differentiation 2), probably via inhibition of selective isoforms
of HDACs (Cao et al., 2011).
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ANTI-TUMOR ACTIVITY OF pH-MODIFIED PECTIN
Pectin can be modiﬁed by treatment at different pHs; the
most studied pH-modiﬁed pectin is the one isolated from cit-
rus (MCP, modiﬁed citrus pectin). pH-modiﬁcation involves an
alkaline treatment that causes ß-elimination reactions, which
results in depolymerization of the polysaccharide backbone and
de-esteriﬁcation of the HG regions. This is followed by an acid
treatment that cleaves neutral sugars, releases the branched regions
of the pectin backbone and preferentially removes arabinose
residues. Thus, arabinogalactans and galactans are generated in
high amounts.
Modiﬁed citrus pectin was mainly studied in Avraham Raz’s
laboratory and has shown strong anti-cancer activities. Injection
of pectin increased the number of tumors detected in lung after
B16-F1melanoma cells implantation inC57BL/6mice probably by
increasing homotypic aggregation between tumor cells whileMCP
signiﬁcantly diminished the number of metastases. MCP which is
rich in galactoside residues seems to impair cell-cell interactions
by competing with endogenous ligands of “galactoside binding
proteins” and more particularly of galectin-3 (Platt and Raz, 1992;
Inohara and Raz, 1994). Raz’s team also showed that orally admin-
istered MCP decreased the number of metastases in lung in rats
injected with prostate cancer MAT-LyLu cells. This decrease was
dose-dependent (Pienta et al., 1995). In 2002, they also evidenced
that MCP decreased the growth of breast (MDA-MB-435) and
colon (LSLiM6) tumors implanted in NRC nu/nu mice as well as
the number of metastases in lung and lymph nodes. These effects
were associated with anti-angiogenic effects since a decrease in
the number of capillaries in vivo and an inhibition of tubulogen-
esis in vitro using HUVEC were observed (Nangia-Makker et al.,
2002). Other works have also evidenced the anti-tumor activity of
MCP. When added to the culture medium of prostate androgen-
independent JCA-1 tumor cells, MCP diminished proliferation
and tritiated thymidine incorporation. MCPdecreased the expres-
sion of nm23, a protein whose expression is inversely correlated
with metastasis in various cancers (Hsieh and Wu, 1995). Hayashi
et al. (2000) showed that oral daily doses of 0.8 and1.6mg/mlMCP
toBalb-Cmice implantedwith colon tumors decreased tumor size,
of respectively 38 and 70%. GCS-100, which is a commercially
available form of modiﬁed pectin, has been shown to be efﬁcient
against different lines of multiple myelomas some of them resis-
tant to chemotherapy, by inducing caspase-3 and -8 activation
as well as PARP cleavage. Modiﬁed pectin-induced apoptosis was
partly inhibited by Z-VAD-fmk, a pan-caspase inhibitor (Chauhan
et al., 2005). A phase II clinical study on prostate cancer patients
showed that PectaSol® MCP signiﬁcantly increased PSADT (PSA
doubling time) in 7out of the 10 cases included in this study (Guess
et al., 2003). PectaSol® and its ameliorated version PectaSol-C® are
cytotoxic for different cancer cell lines: LNCaP, PC3, CASP2.1,
CASP1.1, and BPH-1. In CASP1.1 and PC3 cells, cytotoxicity was
correlated with MAP kinase activation inhibition, increased Bim
protein expression and caspase-3 cleavage (Yan and Katz, 2010).
This product also inhibits the invasive behavior of human breast
and prostate cancer cells in vitro (Jiang et al., 2013).
Galectin-3 seems to be a target of MCP. Galectin-3 protein can
be found intra- and extracellularly and contains a lectin domain.
It has pleiotropic functions, amongst which, it mediates cell-cell
as well as cell-extracellular matrix adhesion, through binding to
glycoconjugates. Indeed, this lectin-domain has a high afﬁnity for
ß-galactoside residues. Galectin-3 expression is dysregulated in
transformed cells, being highly expressed in numerous different
types of cancer cells (Newlaczyl and Yu, 2011). MCP has been
shown to decrease liver metastasis in a mouse colon cancer model,
in a dose-dependent manner. This effect may be linked to the
higher expression of galactin-3 in the liver metastases (Liu et al.,
2008). The relationship between MCP structure and its inhibitory
activity on galectin-3 was investigated in several studies. One such
example is the work by Sathisha et al. (2007) who compared the
activation of pectins from different dietary plants. Pectins rich
in galactose and arabinose and in arabinogalactan signiﬁcantly
inhibited galectin-3-dependent hemagglutination of MDA-MB-
231 cells to erythrocytes (Sathisha et al., 2007). Pectin nearly
mainly composed of RG-I isolated from okra, a tropical plant,
arrested cell cycle of B16F10 cells in G2/M phase and induced
apoptosis probably through interaction with galectin-3 (Vayssade
et al., 2010). Gao et al. (2012) suggested that MCP ability to inhibit
galectin-3 resides in its RG-I regions and more particularly from
galactan, of which the nature of last residue is the most important.
Gunning et al. (2013) conﬁrmed that neutral galactan side chains
did selectively bind to recombinant galectin-3. These active frag-
ments can be obtained by enzymatic treatment of isolated RG-I
regions from potato pectin (Gunning et al., 2009).
In conclusion, MCP displays many anti-metastatic properties
demonstrated both in vitro and in vivo, in various malignancies.
Many of them, if not all, are due to its binding to the pleiotropic
galectin-3 protein which is overexpressed in cancer. Due to its well
tolerance and among other plant-derived products, pectin-derived
GCS-100 is being explored for the maintenance therapy of patient
with B-chronic lymphocytic leukemia relapse (O’Brien and Kay,
2011).
ANTI-TUMOR ACTIVITY OF OTHER FORMS OF MODIFIED PECTIN
Jackson et al. (2007) investigated the apoptosis induction of differ-
ent forms of modiﬁed pectin in prostate cancer cells which were
either androgen-dependent (LNCaP) or androgen-independent
and which were not expressing galactin-3 (LNCaP C4-2). In
their work, citrus pectin and pH-modiﬁed pectin, PectaSol®,
exerted no pro-apoptotic activity while two different forms of
heat-modiﬁed pectins, one commercially available and the other
one prepared in their laboratory, did markedly induce apopto-
sis in the two cell lines (Jackson et al., 2007). They showed HGs,
RG-I, and RG-II taken separately had no cytotoxic activity. Treat-
ment of heat-modiﬁedpectinwithpectinmethylesterase to remove
galacturonosyl carboxymethylesters and/or with endopolygalac-
turonase to cleave non-methylesteriﬁed HG did not result in loss
of activity. On the other hand, mild base treatment that removed
ester bounds destroyed the pro-apoptotic activity. Biological effec-
tiveness thus requires a base-sensitive linkage in OGAs other than
a carboxymethylester bound. Size analyses of the active fragments
suggested low mass (10–20 kDa) oligosaccharides (Jackson et al.,
2007).
Similar results were obtained by Cheng et al. (2011) who tested
the anti-tumor activity of different polysaccharide fractions iso-
lated from ginseng on colon cancer HT-29 cells. While fractions
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rich in HG stopped cell cycle in G2/M phase, fractions rich
in HG and modiﬁed by heat treatment exerted a much higher
anti-proliferative activity, which was accompanied by caspase-3
activation and apoptosis induction (Cheng et al., 2011). Similarly,
potato pectin, rich in HG, inhibited in vitro HT-29 cell prolifera-
tion andprovoked a cell cycle arrest inG2/Mphase. This inhibition
was due to a decrease in cyclin B1 expression and inCDK-1 activity
(Cheng et al., 2013). It is important to note that Kang et al. (2006)
also produced a citrus pectin-derived oligosaccharide, which was
biologically active, by irradiation, i.e., without chemical treatment.
Pectin irradiated with 20 kGy and then dialyzed (WT <10,000)
inhibited cancer cell growth.
IMMUNOPOTENTIATING ACTIVITY OF PECTIN
Some of the components of pectin exert their anti-tumor activity
in vivo by stimulating the immune system. Pectic polysaccha-
rides named angelans and isolated from Angelica gigas Nakai, a
Chinese medicinal plant, are immunopotentiators which increase
immune functions of B lymphocytes, of macrophages and of
“natural killer” cells and which directly activate T helper and
cytotoxic lymphocytes. Angelans have also an anti-metastatic
activity, it inhibits B16F10 cancer cell adhesion to the extra-
cellular matrix as well as its invasion. In a urine model of
colon cancer, apple oligogalactan (AOG) composed of ﬁve sub-
units showed preventive effects against the toxic and carcinogenic
effects of 1,2-dimethylhydrazine and of sodium dextran sul-
fate. The underlying mechanisms included AOG targeting of
the LPS/TLR4/NF-κB pathway by modifying TLR4 membrane
distribution hence preventing LPS binding (Liu et al., 2010). HG-
rich pectin polysaccharides isolated from red ginseng (Ginseng
panax) exert both anti-tumor and immunomodulatory properties
which derived from NO production by macrophages (Choi et al.,
2008). In addition, this immunomodulatory effect ameliorates the
paclitaxel-induced anti-cancer activity in mice with transplanted
B16 melanoma tumors (Shin et al., 2004). As demonstrated by
Chen et al. (2006) pectin effect on LPS-activated macrophages
depends on its DE. Pectin esteriﬁed up to 90% (DE90) inhibits
iNOS and COX2 expression in macrophages much more efﬁ-
ciently than pectin esteriﬁed to 30 or 60%. DE90 pectin also
inhibits MAPK phosphorylation, IKK kinase activity as well as
NF-κB and AP-1 activation. DE90 pectin binds LPS, which could
modify LPS binding to its receptor (Chen et al., 2006). It has also
been shown that PectaSol-C exerts immunostimulating activity in
human blood, activating cytotoxic T cells, B cells and NK cells,
inducing cytotoxicity toward chronic myeloid leukemia K562 cells
(Ramachandran et al., 2011).
MODIFIED PECTIN TO OVERCOME CHEMORESISTANCE
Chemoresistance is a heavy burden in the treatment of can-
cer, especially since a large number of patients already display
metastatic disease at the time of diagnosis. The vast majority
of anti-cancer drugs currently used act by inducing apoptosis
via the intrinsic pathway. Numerous mechanisms underlie can-
cer chemoresistance (Rebucci and Michiels, 2013), but it appears
that galectin-3 which is overexpressed in numerous tumor types,
suppresses cell apoptosis and hence, decreases sensitivity of can-
cer cells to chemotherapeutic drugs (Glinsky and Raz, 2009).
Since MCP has been shown to target galectin-3, several works
were dedicated to delineateMCP-induced possible re-sensitization
of cancer cells to different cytotoxic molecules. Johnson et al.
(2007) showed that galectin-3 targeting via MCP or via a more
speciﬁc inhibitor, lactosyl-L-leucine (LL), decreased malignant
endothelial cell proliferation by themselves and sensitized these
cells to the cytotoxic effect of doxorubicin. These two compounds
also increases metastatic-derived MDA-MB-435 cells sensitivity
to taxol both in vitro and in vivo (Glinsky et al., 2009). GCS-
100, a commercially form of pH-MCP, enhanced bortezomide
and dexamethasone-induced apoptosis in multiple myeloma cells
and decreased viability. The effect was accompanied by a marked
decrease in galectin-3 protein level (Chauhan et al., 2005). GCS-
100 also induced calpain activation in prostate cancer cells that
led to their sensitization to cisplatin treatment (Wang et al., 2010).
Combination of modiﬁed pectin with different anti-cancer agents
may thus represent an efﬁcient new strategy to overcome resistance
in cancer patients.
USE OF PECTIN AS A VEHICLE FOR DRUG DELIVERY IN CANCER
Colon cancer is one of themost common cancers worldwide. Con-
ventional chemotherapy is usually administered by intravenous
injection to target tumor growth and metastases. However, severe
side effects are observed. Oral administration using colon-speciﬁc
delivery systems is expected to augment drug availability at tumor
site while reducing systemic adverse effects. To this purpose,
pectin-based vehicle is ideal since pectin is not digested in the
gastrointestinal tract until it reaches colon, where it is fermented
by residential bacteria, thus releasing the transported drug (for
reviews, Chourasia and Jain, 2003; Patel et al., 2007; Wong et al.,
2011). Different kinds of vehicles with different drugs and differ-
ent chemistry binding or encapsulation have been designed and
tested. Pectinate pellets or microspheres containing drugs led to
prolonged dissolution and drug release in simulating colonic ﬂuid
(Zhang et al., 2011; Elyagoby et al., 2013). Other forms of vehi-
cles like nanoparticles or pectin-based coated-based matrix tablets
have been tested in vitro using colon cancer cells with efﬁcient cell
killing (Kanthamneni et al., 2010; Dev et al., 2011). Nanoparticles,
capsules or microsponges have also been developed. Pharmacoki-
netics evaluation in rats and in rabbits provided evidence for colon
delivery and delayed plasma appearance (Xu et al., 2005; Dev
et al., 2011; Srivastava et al., 2012). However, actual demonstra-
tion for efﬁcient treatment of colon cancer in animal models with
pectin-based anti-cancer agent delivery vehicles is still lacking.
In parallel, pectin-derived biocompatible hydrogel loaded
with different chemotherapeutic drugs have been produced.
Doxorubicin-containing hydrogels displayed cytotoxicity toward
HepG2 cells and inhibited homotypic aggregation of B16
melanoma cells, suggesting that it could also prevent metastasis
in vivo (Takei et al., 2010). Similarly, pectin-coated chitosan gels
encapsulating 5-ﬂuorouracil showed controlled drug release and
cytotoxicity against two cancer cell lines (Puga et al., 2013). Anti-
cancer in vivo activitywas also evidencedusing doxorubicin-pectin
hydrogel in subcutaneous B16melanoma cell tumor inmice (Takei
et al., 2013).
Finally, it is worth mentioning two other types of scaffolds
including pectin- and ﬁbrin-based nano-composites containing
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FIGURE 2 | Schematic representation of the different anti-cancer activities of different forms of pectin.
gemcitabine (Chandran et al., 2013) for the treatment of ovarian
cancer and pectin nanoparticles loaded with methotrexate that
displayed enhanced cytotoxicity toward HepG2 hepatocarcinoma
cells in vitro (Chittasupho et al., 2013).
CONCLUSION
In conclusion, pectin seems to exert anti-tumor activity on dif-
ferent cell lines and in different mice models, and this probably
through different effects. These mechanisms depend on the struc-
ture of pectin or on the modiﬁed form of pectin that is likely
to yield to various active fragments. Differences in extraction
methods, in the plant species from which the pectin is isolated,
in fragmentation techniques as well as in the structural com-
plexity of pectin itself make the characterization of the active
molecule(s) very difﬁcult. The different anti-cancer activities of
different forms of pectin are summarized in Figure 2. As a dietary
ﬁber, pectin is not digested in the upper digestive tract and
could protect cells from mutagenic attacks. In colon, pectin is
fermented, by bacteria, into butyrate that inhibits colon inﬂam-
mation and prevents carcinogenesis. pH-modiﬁed pectin as well
as galactan-rich pectin (RG-I) are capable of interacting with
galectin-3, thus inhibiting cell-cell interactions and cancer cell
metastasis. Furthermore, HG-rich pectin with a high DE com-
petes with LPS for TLR4 binding, hence preventing inﬂammatory
cell activation. Finally, heat-modiﬁed pectin initiates apopto-
sis in cancer cells, in a galectin-3-independent manner. Despite
the fact that the exact structure of these modiﬁed molecules is
not yet known and that neither is their mechanisms of action,
modiﬁed pectin emerges as one of the promising anti-metastatic
drugs, especially if used in combination with more conventional
molecules.
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